UPPSALA, SWEDEN / ACCESSWIRE / September 24, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Monday, September 30, 2024, is the last day for subscription in Biovica's ongoing warrant program, TO3B. Note that some banks and asset managers may have an earlier deadline date for subscription than 30 September 2024. Shareholders should check this with their bank or trustee in order not to miss the chance to subscribe for shares or sell their subscription rights. So far, several key people, including CEO Anders Rylander and chairman Lars Holmqvist, as well as other existing and new investors have committed to subscribe for just over SEK 8.2 million.
Provided that all subscription rights TO3B are fully utilized, the company's share capital will increase by SEK 1,161,035 and the company will be infused with approximately SEK 45.4 million before issue costs.
Contact
Anders Rylander, CEO
Phone: +46 76 666 16 47
E-mail: anders.rylander@biovica.com
Anders Morén, CFO
Phone: +46 73 125 92 46
E-mail: anders.moren@biovica.com
Biovica - Treatment decisions with greater confidence
Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.com
Attachments
Biovica announces subscription commitments in ongoing TO3B program
SOURCE: Biovica International
View the original press release on accesswire.com
